Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin, an over-the-counter (OTC) pain reliever; Nyloxin Extra Strength, a non-narcotic and non-addictive treatment for severe pain; Pet Pain-Away, an OTC pain reliver for dogs and cats; Equine Pain-Away, an OTC topical pain reliever to relieve pain in horses; and Luxury Feet, an OTC pain reliever for foot pain from high heels and stilettos. It is also involved in developing RPI-78M to treat neurological and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, and general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain; and nerve agent countermeasures. The company was incorporated in 2000 and is based in Boca Raton, Florida.